In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

For active investors, the challenge is not typically finding a good stock or an entry point; it’s knowing where to get out. When a stock surges past its previous high, you enter what technical ...

Leonardo of Pisa, known as Fibonacci, introduced Hindu-Arabic numerals to Europe in 1202. His famous number sequence began as a simple rabbit puzzle. Centuries later, this sequence gained fame for its ...

Thank you for signing up! Did you know with a Digital subscription to Yorkshire Post, you can get access to all of our premium content, as well as benefiting from ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Who doesn’t love a good math holiday? Most people know about Pi ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Eleanor has an undergraduate degree in zoology from the University of Reading and a master’s in wildlife documentary production from the University of Salford. Eleanor has an undergraduate degree in ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...